Growth Hormone Testing

Advanced Growth Hormone Testing: High-Sensitivity Immunoassay and Dynamic Stimulation Profiling for Pituitary and Metabolic Assessment

Growth hormone (GH) testing is a critical diagnostic tool in paediatric endocrinology, adult hypopituitarism, sports medicine, and metabolic research, with implications for growth disorders, acromegaly, GH deficiency (GHD), and the evaluation of the somatotropic axis in aging and body composition. However, the pulsatile secretion of GH, its short half-life, and the presence of multiple isoforms and binding proteins make accurate measurement exceptionally challenging. Traditional immunoassays often fail to distinguish the 22-kDa monomeric GH (the predominant bioactive form) from other isoforms and macroforms, leading to significant discrepancies between methods and clinical misinterpretation. Clinicians and researchers seek a testing service that not only provides accurate GH quantification but also integrates dynamic stimulation and suppression tests, isoform-specific measurement, and sophisticated interpretation algorithms. Our laboratory delivers a comprehensive GH testing programme using ultrasensitive chemiluminescent immunoassays with isoform selectivity, confirmatory mass spectrometry, and standardised dynamic protocols, offering a level of precision and clinical clarity that exceeds conventional approaches.

The Clinical Imperative for Isoform-Specific and Dynamic GH Assessment

Serum GH exists in several molecular forms, with the 22‑kDa monomer being the most abundant and biologically active, while 20‑kDa, placental variants, and glycosylated isoforms have reduced receptor-binding affinity. Moreover, GH-binding protein (GHBP) and anti-GH antibodies can interfere with immunoassays, producing falsely elevated or depressed values. Our standard GH profile includes total GH (22‑kDa specific) by a highly sensitive, monoclonal antibody-based chemiluminescence assay that exhibits minimal cross-reactivity with other isoforms, validated against the WHO International Standard 98/574. For research and complex cases, we offer GH isoform fractionation by size-exclusion chromatography followed by LC-MS/MS, allowing the quantification of the 22‑kDa fraction, 20‑kDa fraction, and higher-molecular-weight aggregates (macro-GH) to identify patients with macro-GH syndrome—a benign condition that can mimic elevated GH levels. Additionally, we measure insulin-like growth factor‑1 (IGF‑1) and IGF-binding protein‑3 (IGFBP‑3) as stable, integrated markers of GH secretion, providing a complementary perspective that is less affected by pulsatility.

Recognising that a single random GH measurement has limited diagnostic utility, our core service is built around standardised dynamic stimulation tests, including the insulin tolerance test (ITT) (the gold standard for GH deficiency), the GHRH-arginine stimulation test, the glucagon stimulation test, and the clonidine or levodopa stimulation tests for paediatric patients. For acromegaly screening, we perform the oral glucose tolerance test (OGTT) with GH suppression, measuring GH at 0, 30, 60, 90, and 120 minutes post-glucose load. All dynamic protocols are conducted under medical supervision with rigorous safety monitoring, and we provide comprehensive timed curves with calculated peak GH and nadir GH values, along with integrated area-under-the-curve (AUC) analysis. We also offer provocative testing for GH reserve using the combined administration of GHRH plus arginine, which has superior sensitivity and specificity in adults. Our reporting includes decision thresholds based on the latest consensus guidelines (Endocrine Society, PES, and GH Research Society), stratified by body mass index and age.

Our Analytical Capabilities: Ultrasensitive Detection and Isoform Resolution

Our primary GH immunoassay is based on a fully automated two‑site chemiluminescent technology with a functional sensitivity of 0.02 ng/mL (mIU/L conversion factor: 1 ng/mL ≈ 3 mIU/L), ensuring accurate measurement even in profoundly deficient states. The assay is calibrated against the WHO 98/574 standard and exhibits zero cross‑reactivity with prolactin, hCG, and other pituitary hormones. For confirmation of ambiguous results, we deploy a high-resolution LC-MS/MS method using immunoaffinity enrichment and isotope‑labelled internal standards, achieving a limit of quantification (LOQ) of 0.1 ng/mL for the 22‑kDa isoform, with the ability to simultaneously monitor the 20‑kDa isoform and detect the presence of macro-GH complexes. This mass spectrometric approach is essential when GH immunoassay results are discordant with clinical findings or when the patient is receiving recombinant GH therapy, where the presence of anti-GH antibodies can cause assay interference.

For IGF‑1 and IGFBP‑3, we use electrochemiluminescence immunoassays with extensive standardisation to WHO reference materials, providing an LOQ for IGF‑1 of 3 ng/mL and a wide dynamic range. We further offer a growth hormone stimulation test panel that includes sequential GH measurements, IGF‑1, and cortisol (for ITT) to simultaneously assess the entire pituitary‑adrenal axis. Our laboratory is equipped with automated robotic systems for serial sampling, ensuring accurate time-point collection and immediate sample processing to minimise degradation. We also provide calculated indices, such as the GH peak/IGF‑1 ratio and the GH suppression index (GH nadir during OGTT), which have prognostic value in acromegaly and GH deficiency, respectively.

Regulatory Compliance and Quality Assurance

All GH testing services are conducted under CLIA '88 and CAP accreditation, with rigorous adherence to the CLSI C49-A guidelines for immunoassay validation. Our dynamic protocols are standardised using published algorithms and we provide detailed pre-test instructions to patients to ensure optimal conditions (e.g., fasting, sleep deprivation, and medication washout). Each dynamic test includes quality controls at each time point, and our reports are accompanied by a graphical representation of the response curve, reference values, and interpretive commentary highlighting whether the peak or nadir meets the diagnostic criteria for GH deficiency or acromegaly. We participate in the UK NEQAS for GH and IGF‑1 and the CDC IGF‑1 Standardization Program, ensuring our results are comparable across centres and over time. Our final reports also include a clinical decision support section that integrates the biochemical data with the patient’s sex, age, BMI, and pubertal stage (for children) to provide a personalised probabilistic assessment of GH status.

Our Distinctive Advantages in Growth Hormone Testing

Our laboratory offers several unique benefits that directly address the challenges of GH testing. First, we provide a complete “dynamic + static” package that combines stimulation or suppression testing with concomitant measurement of IGF‑1 and IGFBP‑3 in a single episode, reducing the need for multiple visits and improving diagnostic efficiency. Second, our isoform-resolved LC-MS/MS confirmation is a rare capability that resolves cases of suspected macro-GH and assay interference, providing definitive answers for patients with discordant results. Third, we have a specialised paediatric dynamic testing protocol with age‑ and pubertal stage‑specific reference intervals and lower stimulation thresholds, which are critical for diagnosing GHD in children—a group in whom cut‑offs differ significantly from adults.

Fourth, our real-time monitoring system during dynamic tests allows for immediate safety checks (e.g., hypoglycaemia during ITT) and we provide on-call medical oversight by board‑certified endocrinologists throughout the test. Fifth, we offer longitudinal growth hormone monitoring packages for patients on recombinant human GH (rhGH) therapy, with trend analysis of IGF‑1, IGFBP‑3, and GH autoantibody titres, which is essential for dose titration and detecting poor compliance or antibody formation. Our electronic reporting system includes a dynamic growth chart overlay for paediatric cases, showing the patient's height velocity, bone age, and hormonal data in a single integrated view. We also offer consultative interpretation with our endocrine team to discuss complex cases, such as patients with borderline GH peaks, previous pituitary surgery, or those transitioning from paediatric to adult care.

Specimen Types and Clinical Applications

GH testing is validated on serum and plasma (EDTA), with strict requirements for fasting, rest, and avoidance of strenuous exercise before sampling—detailed instructions are provided with every test kit. For dynamic tests, we provide a comprehensive protocol kit including glucose solutions, arginine, and other stimulants, along with standardised collection tubes and time‑point scheduling. Clinical applications span the diagnosis of childhood growth failure, adult GHD (with appropriate clinical features such as reduced bone density, adverse lipid profile, and impaired quality of life), acromegaly monitoring after surgery or medical therapy, and evaluation of GH excess in pituitary incidentalomas. Our services are also employed in the screening of athletes (although we adhere strictly to anti‑doping regulations and offer only clinical, not performance‑enhancing, testing), and in research studies on sarcopenia, frailty, and the influence of the GH/IGF‑1 axis on longevity.

Innovation and Research Engagement

We are actively involved in developing novel biomarkers of GH action, including collagen markers (e.g., PIIINP) and osteocalcin, which may serve as peripheral readouts of tissue responsiveness. We are also refining a machine-learning model that integrates GH peak, IGF‑1, clinical parameters, and genetic variants to predict the individual response to rhGH therapy in children with idiopathic GHD. Our ongoing collaborations with academic paediatric endocrinology units generate updated normative data for stimulation tests, considering the secular trends in growth and obesity. These research activities ensure that our testing services remain at the cutting edge of evidence-based medicine.

Client Support and Service Model

We understand that GH testing, particularly dynamic testing, requires careful planning and patient preparation. We assign a dedicated test coordinator to assist with scheduling, send detailed preparatory checklists, and provide a 24‑hour helpline for any pre‑test questions. During dynamic testing, we offer a comfortable clinical setting with continuous supervision, and we provide a light meal post‑test. Results are delivered within 24 hours for basal samples and within 48 hours for full dynamic panels, with priority STAT options for urgent clinical decisions. Our pricing is transparent and includes all consumables, stimulant agents, and medical oversight. For centres with multiple dynamic test requests, we offer bulk scheduling and volume‑based discounts. We also provide free educational seminars on GH testing interpretation and the latest guidelines, supporting clinicians in optimising their diagnostic pathways.

Conclusion: Precision GH Testing for Comprehensive Pituitary Assessment

Growth hormone testing, when elevated to a multi‑modal, isoform‑specific, and dynamic discipline, transforms from a problematic single‑measurement assay to a sophisticated endocrine investigative tool. Our laboratory has engineered this comprehensive ecosystem—combining ultrasensitive and isoform‑selective immunoassays, confirmatory mass spectrometry, standardised dynamic stimulation protocols, and expert clinical interpretation—to deliver definitive answers for patients with suspected GH disorders. Whether the clinical scenario is a short child, an adult with fatigue and poor quality of life, or a patient with a pituitary tumour, our services provide the accuracy, depth, and clinical relevance required for optimal management.

We invite you to access our growth hormone testing services. Our dedicated team of endocrine scientists and clinicians is ready to partner with you, from test selection through result interpretation, ensuring you receive not only data but also actionable insights. Choose our laboratory for excellence in pituitary diagnostics, supported by innovation, quality, and a deep commitment to patient-centred care.